C. Balch, J. Gershenwald, S. Soong, and J. Thompson, Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate, Journal of Surgical Oncology, vol.17, issue.4, pp.379-85, 2011.
DOI : 10.1002/jso.21876

E. Korn, P. Liu, S. Lee, J. Chapman, D. Niedzwiecki et al., Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials, Journal of Clinical Oncology, vol.26, issue.4, pp.527-561, 2008.
DOI : 10.1200/JCO.2007.12.7837

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466

K. Flaherty, I. Puzanov, K. Kim, A. Ribas, G. Mcarthur et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-819, 2010.
DOI : 10.1056/NEJMoa1002011

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.26, pp.2507-2523, 2011.

P. Lito, C. Pratilas, E. Joseph, M. Tadi, E. Halilovic et al., Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAF V600E melanomas, Cancer Cell, vol.5, pp.668-82, 2012.

P. Poulikakos, C. Zhang, G. Bollag, K. Shokat, and N. Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, vol.6, issue.7287, pp.427-457, 2010.
DOI : 10.1038/nature08902

R. Sullivan and K. Flaherty, MAP kinase signaling and inhibition in melanoma, Oncogene, vol.18, issue.19, pp.2373-2382
DOI : 10.1038/onc.2012.345

P. Ascierto, D. Schadendorf, C. Berking, S. Agarwala, C. Van-herpen et al., MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study, The Lancet Oncology, vol.14, issue.3, pp.162249-56, 2013.
DOI : 10.1016/S1470-2045(13)70024-X

R. Lo, Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas, Pharmacogenomics, vol.13, issue.2, pp.125-133, 2012.
DOI : 10.2217/pgs.11.166

R. Corcoran, J. Settleman, and J. Engelman, Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers, Oncotarget, vol.2, issue.4, pp.336-382, 2011.
DOI : 10.18632/oncotarget.262

J. Sosman, A. Pavlick, L. Schuchter, K. Lewis, G. Mcarthur et al., Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAF V600E melanoma, J Clin Oncol, vol.8503, p.30, 2012.

R. Nazarian, H. Shi, Q. Wang, X. Kong, R. Koya et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.66, issue.7326, pp.973-980, 2010.
DOI : 10.1038/nature09626

J. Villanueva, A. Vultur, J. Lee, R. Somasundaram, M. Fukunaga-kalabis et al., Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, issue.6, pp.683-95, 2010.
DOI : 10.1016/j.ccr.2010.11.023

K. Flaherty, J. Infante, A. Daud, R. Gonzalez, R. Kefford et al., Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations, New England Journal of Medicine, vol.367, issue.18, pp.1694-703, 2012.
DOI : 10.1056/NEJMoa1210093

H. Zhang, A. Berezov, Q. Wang, G. Zhang, J. Drebin et al., ErbB receptors: from oncogenes to targeted cancer therapies, Journal of Clinical Investigation, vol.117, issue.8, pp.2051-2059, 2007.
DOI : 10.1172/JCI32278

A. Hsieh and M. Moasser, Targeting HER proteins in cancer therapy and the role of the non-target HER3, British Journal of Cancer, vol.16, issue.4, pp.453-457, 2007.
DOI : 10.1038/nrc2127

A. Ocana, F. Vera-badillo, B. Seruga, A. Templeton, A. Pandiella et al., HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis, JNCI Journal of the National Cancer Institute, vol.105, issue.4, pp.266-73, 2013.
DOI : 10.1093/jnci/djs501

B. Schoeberl, E. Pace, J. Fitzgerald, B. Harms, L. Xu et al., Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis, Science Signaling, vol.2, issue.77, 2009.
DOI : 10.1126/scisignal.2000352

N. Sergina, M. Rausch, D. Wang, J. Blair, B. Hann et al., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3, Nature, vol.9, issue.7126, pp.437-478, 2007.
DOI : 10.1038/nature05474

J. Garrett, M. Olivares, C. Rinehart, N. Granja-ingram, V. Sánchez et al., Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase, Proceedings of the National Academy of Sciences, vol.108, issue.12, pp.5021-5027, 2011.
DOI : 10.1073/pnas.1016140108

A. Chakrabarty, V. Sanchez, M. Kuba, C. Rinehart, and C. Arteaga, Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors, Proceedings of the National Academy of Sciences, vol.109, issue.8, pp.2718-2741, 2012.
DOI : 10.1073/pnas.1018001108

L. Aurisicchio, E. Marra, G. Roscilli, R. Mancini, and G. Ciliberto, The promise of anti-ErbB3 monoclonals as new cancer therapeutics, Oncotarget, vol.3, issue.8, pp.744-58, 2012.
DOI : 10.18632/oncotarget.550

F. Belleudi, E. Marra, F. Mazzetta, L. Fattore, M. Giovagnoli et al., Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells, Cell Cycle, vol.66, issue.7, pp.1455-67, 2012.
DOI : 10.4161/cc.19861
URL : https://hal.archives-ouvertes.fr/pasteur-00961644

L. Aurisicchio, E. Marra, L. Luberto, F. Carlomosti, D. Vitis et al., Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors, Journal of Cellular Physiology, vol.104, issue.10, pp.3318-3326, 2012.
DOI : 10.1002/jcp.24037

H. Yang, B. Higgins, K. Kolinsky, K. Packman, Z. Go et al., RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models, Cancer Research, vol.70, issue.13, pp.72045518-72045545, 2010.
DOI : 10.1158/0008-5472.CAN-10-0646

E. Abel, K. Basile, C. Kugel, A. Witkiewicz, K. Le et al., Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3, Journal of Clinical Investigation, vol.123, issue.5, pp.2155-68, 2013.
DOI : 10.1172/JCI65780DS1

. Fattore, Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies, Journal of Translational Medicine, vol.11, issue.1, p.180, 2013.
DOI : 10.1126/scisignal.2000352
URL : https://hal.archives-ouvertes.fr/pasteur-01053843